Developer docs
API playgroundTry for free, no card

Search company profiles

Synthace

Full company profile

uuid0000i5x

Namestring
Synthace
Legal namestring
Synthace Limited
Websiteurl
synthace.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Synthace is a London-headquartered SaaS company, founded in 2011 as a spin-out of University College London, that builds a cloud-based digital experiment platform for life-sciences R&D. The platform provides biologists with a no-code graphical interface to design, automate, and execute biological experiments, translating workflows into liquid-handling instructions for instruments from Hamilton, Tecan, SPT Labtech, BioTek, Repligen, and Beckman Coulter. Its flagship add-on, Synthace DOE, brings adaptive Design of Experiments capabilities with Builder, Planner, Preview, Runner, Experiment Map, and Response Analysis modules, and a 2023 integration with OpenAI's ChatGPT enables natural-language experiment design. The platform also auto-captures raw and metadata with full DOE context, producing the high-dimensional, structured datasets positioned as inputs to downstream AI/ML applications.

Synthace monetizes primarily through annual enterprise subscriptions to the platform and its protocols, supplemented by professional services such as DOE and Automation Masterclass training and embedded Field Application Scientist support. Go-to-market is enterprise field sales targeting top global pharmaceutical and biotechnology companies, with proof-of-concept-led deployments, channel partnerships with five liquid-handler OEMs, and a 2025 listing on Microsoft Azure Marketplace. The company reported more than 225% ARR growth in FY2020 and expanded from four to eight of the world's top pharma customers by 2022, with multiple accounts at six-figure ARR.

The company is venture-backed (most recent disclosed round a $35M Series C in November 2021 led by Horizons Ventures and Sofinnova Partners), has 51-100 employees with a US regional headquarters in Boston, and operates under CEO Guy Levy-Yurista with Dr. Donald Deieso as Board Chair. Named customers include AstraZeneca, Oxford Biomedica, Ipsen, Charles River Laboratories, MSD/Merck, UCL, and Cambridge Consultants, spanning pharma, cell and gene therapy, CROs, diagnostics, and academic research.

Short descriptiontext

Synthace provides a cloud-based, no-code digital experiment platform that lets biologists design, automate, and run biological experiments across multiple liquid-handler brands, with Synthace DOE and ChatGPT integration enabling AI-ready data generation for global pharmaceutical and biotechnology customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lab automation software, design of experiments, bioprocess optimization, life sciences R&D, cloud experiment platform
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAO
Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code3 codes
  • Software Publishers5132
  • Software Publishers513210
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
Product category
Life Sciences R&D Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Software Platform Subscription
TypeSubscription Recurring
Description

Cloud-based software platform for biological experimentation, likely sold as annual subscriptions to enterprise pharmaceutical and biotech customers.

synthace.com
2Protocols and Trusted Protocols
TypeSubscription Recurring
Description

Pre-built, verified protocols for common biological experiments (ELISA, qPCR, purification, construct assembly) delivered as part of the platform.

synthace.com
3Training and On-Site Support
TypeProfessional Services
Description

Specialist support services including DOE training course, Automation Masterclass, and on-site implementation support from field application scientists.

synthace.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Enterprise platform with specialist support
ModelSubscriptionBilling cadenceAnnual
Notes

Multiple customers surpassed six-figure annual recurring revenues. Pricing likely varies based on organization size, number of users, and scope of implementation.

synthace.com
2Training and education services
ModelSubscriptionBilling cadenceAnnual
Notes

Free DOE training course available; premium training includes DOE Masterclass and Automation Masterclass.

synthace.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Synthace DOE
Description

An adaptive Design of Experiments (DOE) solution enabling scientists to quickly and easily define, execute, and analyze experiments without the need for statistical software or expertise. Built specifically for biologists.

synthace.com
+1 more record
Core offering1 text field

Synthace sells a cloud-based Life Sciences R&D Digital Experiment Platform (SaaS) that lets biologists design, automate, run, and analyze biological experiments without writing code. The platform translates experimental workflows into liquid-handling instructions for major lab robots (Hamilton, Tecan, SPT Labtech, BioTek, Beckman, Gilson, Repligen) and includes the Synthace DOE Design of Experiments module, in silico simulation, automated contextual data capture, and a ChatGPT integration, producing AI-ready high-dimensional datasets. It is sold as annual enterprise subscriptions to pharmaceutical, biotech, diagnostics, and academic customers, supplemented by specialist training and on-site implementation support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Experimental throughput increased by over tenfold
+6 more records
Product overview1 text field

Synthace offers a cloud-based digital experiment platform for life science R&D, consisting of the core Synthace Platform as the central operating system for biology, complemented by specialized modules including Synthace DOE (Design of Experiments tool), Automated Multivariate Experiments, Assay Development, Media Optimization, and Miniaturized Purification services. The platform enables biologists to design, automate, and run experiments without coding, generating AI-ready high dimensional data. Additional offerings include training programs (DOE Training Course, DOE Masterclass, Automation Masterclass) and specialized features like the Cherry Picker for liquid transfer specification.

Product and service3 records
1Synthace Platform
CategoryCloud-based R&D platform
Description

Cloud-based R&D software platform that enables biologists to design, automate, and run biological experiments without coding, translating workflows into liquid-handling instructions for multiple lab robots and generating high-dimensional, fully contextualized datasets for AI analysis. Sold on annual subscription to enterprise pharmaceutical, biotech, diagnostics, and academic customers.

2Synthace DOE
CategoryDesign of Experiments software module
Description

Adaptive Design of Experiments software built specifically for biologists, enabling scientists to define, execute, and analyze experiments without statistical software expertise. Includes Builder (drag-and-drop DOE workflows), Planner (automatic calculations), Preview (in-silico simulation), Runner (one-click execution), Experiment Map, and Response Analysis (predictive modeling of outcomes).

3Miniaturized Purification
CategoryBioprocess purification protocol
Description

Protocol and service offering for miniaturized protein purification optimization on Tecan instruments (including the Te-Chrom system), enabling time and cost savings in bioprocessing labs through smaller-scale purification workflows.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-01
Description

Collaboration announced at SLAS2026 for scalable design of experiments software. Partnership to provide enhanced assay solutions for the global pharmaceutical industry with more robust, faster and cost-effective assays.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Partnership to bring Synthace platform to Microsoft Azure cloud infrastructure, enabling broader accessibility and integration with Azure services.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic go-to-market partnership for purification optimization. Collaboration to accelerate purification optimization in process development through augmented lab automation using Te-Chrom system.

Strategic tierCoreTypeTechnology or Integration
Description

Go-to-market partnership for assay execution. Partnership on VPS4B screening platform announced at SLAS2026.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic go-to-market partnership for automated experimentation on Hamilton liquid handling platforms.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic go-to-market partnership for assay development and execution on BioTek instruments.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic go-to-market partnership for lab equipment integration.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on bioprocessing workflows for cell and gene therapy development. Joint work on Bioprocessing 4.0 report.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on flexible data and physical automation infrastructure for cell and gene therapy development. Joint work integrating in-line analytics with lab automation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership to unlock full potential of biology through joint development of automated workflows and optimization of qPCR assays.

11UCL
Strategic tierMinorTypeStrategic or Co-development Partner
Description

UCL selected Synthace to help make digital, cloud-based lab work a reality, bridging gap between digital and physical spaces.

synthace.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to accelerate novel therapeutic development through automation, combining biopharma expertise with integrative software.

13Pistoia Alliance
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Synthace rejoined the Pistoia Alliance to support development and adoption of standards and FAIR (findable, accessible, reusable and interoperable) working practices.

synthace.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on programming biological systems research, changing the way research on programming biological systems is conducted.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration to develop biomanufacturing platform for improved biologics manufacturing.

16Dow AgroSciences
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration using Synthace platform for agricultural science applications.

synthace.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Benchling is a cloud-based R&D platform for life sciences spanning ELN, LIMS, and registry functionality. It directly competes with Synthace for enterprise pharma and biotech R&D budgets, offering a broader platform that overlaps with Synthace's experiment-design and structured-data value proposition.

TypeDirect peer
Description

Dotmatics (acquired by Siemens) provides an R&D scientific platform including ELN, LIMS, and data visualization used by major pharma. It targets the same enterprise life sciences customer base as Synthace and competes for the scientific data management and experiment informatics wallet share.

TypeDirect peer
Description

LabVantage is an enterprise LIMS and laboratory informatics platform widely deployed in pharma and biotech. It overlaps with Synthace in the lab data management and structured experiment capture space, particularly with regulated pharma customers.

TypeDirect peer
Description

LabWare provides LIMS and ELN software used by major pharmaceutical and biotech companies. As an established laboratory informatics vendor, it competes with Synthace for the same enterprise pharma R&D software budgets.

TypeDirect peer
Description

TetraScience is a scientific data cloud platform that ingests instrument data and structures it for analytics and AI/ML use. It directly addresses the same 'AI-ready data' problem Synthace solves, serving biotech and pharma R&D customers with data lakehouse architectures.

TypeDirect peer
Description

Genedata provides scientific data management and analysis platforms for biopharma R&D, including screening, biologics, and biomarker workflows. It serves large pharma customers with similar experiment informatics needs to Synthace.

TypeEmerging player
Description

IDBS provides the Polar ELN and bioprocess data management solutions. IDBS is already a Synthace integration partner for the ELN workflow but competes in adjacent bioprocess data capture and structured experiment informatics for pharma customers.

TypeEmerging player
Description

Scitara offers a Scientific Integration Platform (SIP) for connecting lab instruments and software systems. It overlaps with Synthace's device-agnostic integration and structured data capture value proposition, particularly for pharma labs with diverse instrument fleets.

TypeEmerging player
Description

LabArchives is an ELN platform widely adopted in academic and commercial life sciences research. It competes for the lab-notebook and structured experiment capture layer of the stack that Synthace also addresses.

TypeOthers
Description

Insitro is an AI-driven drug discovery company that combines ML with high-throughput biology. While not a direct SaaS peer, it shares Synthace's thesis that AI in drug discovery requires structured, high-dimensional experimental data, making it an adjacent player in the same value chain.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration10 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synthace

Life Sciences R&D Softwaresynthace.com

Synthace provides a cloud-based, no-code digital experiment platform that lets biologists design, automate, and run biological experiments across multiple liquid-handler brands, with Synthace DOE and ChatGPT integration enabling AI-ready data generation for global pharmaceutical and biotechnology customers.

What Synthace does

Synthace is a London-headquartered SaaS company, founded in 2011 as a spin-out of University College London, that builds a cloud-based digital experiment platform for life-sciences R&D. The platform provides biologists with a no-code graphical interface to design, automate, and execute biological experiments, translating workflows into liquid-handling instructions for instruments from Hamilton, Tecan, SPT Labtech, BioTek, Repligen, and Beckman Coulter. Its flagship add-on, Synthace DOE, brings adaptive Design of Experiments capabilities with Builder, Planner, Preview, Runner, Experiment Map, and Response Analysis modules, and a 2023 integration with OpenAI's ChatGPT enables natural-language experiment design. The platform also auto-captures raw and metadata with full DOE context, producing the high-dimensional, structured datasets positioned as inputs to downstream AI/ML applications.

Synthace monetizes primarily through annual enterprise subscriptions to the platform and its protocols, supplemented by professional services such as DOE and Automation Masterclass training and embedded Field Application Scientist support. Go-to-market is enterprise field sales targeting top global pharmaceutical and biotechnology companies, with proof-of-concept-led deployments, channel partnerships with five liquid-handler OEMs, and a 2025 listing on Microsoft Azure Marketplace. The company reported more than 225% ARR growth in FY2020 and expanded from four to eight of the world's top pharma customers by 2022, with multiple accounts at six-figure ARR.

The company is venture-backed (most recent disclosed round a $35M Series C in November 2021 led by Horizons Ventures and Sofinnova Partners), has 51-100 employees with a US regional headquarters in Boston, and operates under CEO Guy Levy-Yurista with Dr. Donald Deieso as Board Chair. Named customers include AstraZeneca, Oxford Biomedica, Ipsen, Charles River Laboratories, MSD/Merck, UCL, and Cambridge Consultants, spanning pharma, cell and gene therapy, CROs, diagnostics, and academic research.

Synthace firmographics

Firmographics
Name
Synthace
Legal name
Synthace Limited
Website
https://synthace.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Synthace provides a cloud-based, no-code digital experiment platform that lets biologists design, automate, and run biological experiments across multiple liquid-handler brands, with Synthace DOE and ChatGPT integration enabling AI-ready data generation for global pharmaceutical and biotechnology customers.
Ownership category
akta.pro rank

Synthace industry classification

Industry
Product category
Life Sciences R&D Software
NAICS
Software Publishers (5132), Software Publishers (513210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAO
Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Lab automation software
  • Design of experiments
  • Bioprocess optimization
  • Life sciences R&D
  • Cloud experiment platform

Where Synthace is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Synthace business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Software Platform Subscription: Cloud-based software platform for biological experimentation, likely sold as annual subscriptions to enterprise pharmaceutical and biotech customers.
  2. Protocols and Trusted Protocols: Pre-built, verified protocols for common biological experiments (ELISA, qPCR, purification, construct assembly) delivered as part of the platform.
  3. Training and On-Site Support: Specialist support services including DOE training course, Automation Masterclass, and on-site implementation support from field application scientists.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise platform with specialist support
SubscriptionAnnualTraining and education services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Synthace product offering

Product offering

Core offering

Synthace sells a cloud-based Life Sciences R&D Digital Experiment Platform (SaaS) that lets biologists design, automate, run, and analyze biological experiments without writing code. The platform translates experimental workflows into liquid-handling instructions for major lab robots (Hamilton, Tecan, SPT Labtech, BioTek, Beckman, Gilson, Repligen) and includes the Synthace DOE Design of Experiments module, in silico simulation, automated contextual data capture, and a ChatGPT integration, producing AI-ready high-dimensional datasets. It is sold as annual enterprise subscriptions to pharmaceutical, biotech, diagnostics, and academic customers, supplemented by specialist training and on-site implementation support.

Product overview

Synthace offers a cloud-based digital experiment platform for life science R&D, consisting of the core Synthace Platform as the central operating system for biology, complemented by specialized modules including Synthace DOE (Design of Experiments tool), Automated Multivariate Experiments, Assay Development, Media Optimization, and Miniaturized Purification services. The platform enables biologists to design, automate, and run experiments without coding, generating AI-ready high dimensional data. Additional offerings include training programs (DOE Training Course, DOE Masterclass, Automation Masterclass) and specialized features like the Cherry Picker for liquid transfer specification.

Differentiator

Problem solved

Functional benefit

Brands

  • Synthace DOE: An adaptive Design of Experiments (DOE) solution enabling scientists to quickly and easily define, execute, and analyze experiments without the need for statistical software or expertise. Built specifically for biologists.
  • Antha

Products and services

  • Synthace Platform Cloud-based R&D software platform that enables biologists to design, automate, and run biological experiments without coding, translating workflows into liquid-handling instructions for multiple lab robots and generating high-dimensional, fully contextualized datasets for AI analysis. Sold on annual subscription to enterprise pharmaceutical, biotech, diagnostics, and academic customers.
  • Synthace DOE Adaptive Design of Experiments software built specifically for biologists, enabling scientists to define, execute, and analyze experiments without statistical software expertise. Includes Builder (drag-and-drop DOE workflows), Planner (automatic calculations), Preview (in-silico simulation), Runner (one-click execution), Experiment Map, and Response Analysis (predictive modeling of outcomes).
  • Miniaturized Purification Protocol and service offering for miniaturized protein purification optimization on Tecan instruments (including the Te-Chrom system), enabling time and cost savings in bioprocessing labs through smaller-scale purification workflows.

Quantifiable outcome

  • Experimental throughput increased by over tenfold
  • +6 more outcomes

Companies that use Synthace

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Synthace technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability5 records

Feature8 records

Synthace partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core and minor.

  • Charles River LaboratoriescoreStrategic or Co-development Partner · 1 November 2022Collaboration announced at SLAS2026 for scalable design of experiments software. Partnership to provide enhanced assay solutions for the global pharmaceutical industry with more robust, faster and cost-effective assays.
  • MicrosoftcoreStrategic or Co-development Partner · 1 January 2022Partnership to bring Synthace platform to Microsoft Azure cloud infrastructure, enabling broader accessibility and integration with Azure services.
  • TecancoreTechnology or IntegrationStrategic go-to-market partnership for purification optimization. Collaboration to accelerate purification optimization in process development through augmented lab automation using Te-Chrom system.
  • SPT LabtechcoreTechnology or IntegrationGo-to-market partnership for assay execution. Partnership on VPS4B screening platform announced at SLAS2026.
  • HamiltoncoreTechnology or IntegrationStrategic go-to-market partnership for automated experimentation on Hamilton liquid handling platforms.
  • BioTekcoreTechnology or IntegrationStrategic go-to-market partnership for assay development and execution on BioTek instruments.
  • RepligencoreTechnology or IntegrationStrategic go-to-market partnership for lab equipment integration.
  • Oxford BioMedicacoreStrategic or Co-development PartnerCollaboration on bioprocessing workflows for cell and gene therapy development. Joint work on Bioprocessing 4.0 report.
  • Cell and Gene Therapy CatapultcoreStrategic or Co-development PartnerCollaboration on flexible data and physical automation infrastructure for cell and gene therapy development. Joint work integrating in-line analytics with lab automation.
  • Cambridge ConsultantsminorStrategic or Co-development PartnerPartnership to unlock full potential of biology through joint development of automated workflows and optimization of qPCR assays.
  • UCLminorStrategic or Co-development PartnerUCL selected Synthace to help make digital, cloud-based lab work a reality, bridging gap between digital and physical spaces.
  • IpsencoreStrategic or Co-development PartnerPartnership to accelerate novel therapeutic development through automation, combining biopharma expertise with integrative software.
  • Pistoia AllianceminorStrategic or Co-development PartnerSynthace rejoined the Pistoia Alliance to support development and adoption of standards and FAIR (findable, accessible, reusable and interoperable) working practices.
  • Microsoft ResearchcoreStrategic or Co-development PartnerCollaboration on programming biological systems research, changing the way research on programming biological systems is conducted.
  • MSD (Merck)coreStrategic or Co-development PartnerCollaboration to develop biomanufacturing platform for improved biologics manufacturing.
  • Dow AgroSciencesminorStrategic or Co-development PartnerCollaboration using Synthace platform for agricultural science applications.

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

Synthace competitors and assessment

Company assessment

Direct peers

  • Benchling: Benchling is a cloud-based R&D platform for life sciences spanning ELN, LIMS, and registry functionality. It directly competes with Synthace for enterprise pharma and biotech R&D budgets, offering a broader platform that overlaps with Synthace's experiment-design and structured-data value proposition.
  • Dotmatics: Dotmatics (acquired by Siemens) provides an R&D scientific platform including ELN, LIMS, and data visualization used by major pharma. It targets the same enterprise life sciences customer base as Synthace and competes for the scientific data management and experiment informatics wallet share.
  • LabVantage: LabVantage is an enterprise LIMS and laboratory informatics platform widely deployed in pharma and biotech. It overlaps with Synthace in the lab data management and structured experiment capture space, particularly with regulated pharma customers.
  • LabWare: LabWare provides LIMS and ELN software used by major pharmaceutical and biotech companies. As an established laboratory informatics vendor, it competes with Synthace for the same enterprise pharma R&D software budgets.
  • TetraScience: TetraScience is a scientific data cloud platform that ingests instrument data and structures it for analytics and AI/ML use. It directly addresses the same 'AI-ready data' problem Synthace solves, serving biotech and pharma R&D customers with data lakehouse architectures.
  • Genedata: Genedata provides scientific data management and analysis platforms for biopharma R&D, including screening, biologics, and biomarker workflows. It serves large pharma customers with similar experiment informatics needs to Synthace.

Emerging players

  • IDBS: IDBS provides the Polar ELN and bioprocess data management solutions. IDBS is already a Synthace integration partner for the ELN workflow but competes in adjacent bioprocess data capture and structured experiment informatics for pharma customers.
  • Scitara: Scitara offers a Scientific Integration Platform (SIP) for connecting lab instruments and software systems. It overlaps with Synthace's device-agnostic integration and structured data capture value proposition, particularly for pharma labs with diverse instrument fleets.
  • LabArchives: LabArchives is an ELN platform widely adopted in academic and commercial life sciences research. It competes for the lab-notebook and structured experiment capture layer of the stack that Synthace also addresses.

Others

  • Insitro: Insitro is an AI-driven drug discovery company that combines ML with high-throughput biology. While not a direct SaaS peer, it shares Synthace's thesis that AI in drug discovery requires structured, high-dimensional experimental data, making it an adjacent player in the same value chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Synthace social profiles

Digital presence

Synthace compliance and trust

Trust signal

Compliance2 records

Synthace financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synthace leadership team

Management profile

Number of profiles

Profiles9 records

Synthace funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synthace M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synthace

What does Synthace do?

Synthace sells a cloud-based Life Sciences R&D Digital Experiment Platform (SaaS) that lets biologists design, automate, run, and analyze biological experiments without writing code. The platform translates experimental workflows into liquid-handling instructions for major lab robots (Hamilton, Tecan, SPT Labtech, BioTek, Beckman, Gilson, Repligen) and includes the Synthace DOE Design of Experiments module, in silico simulation, automated contextual data capture, and a ChatGPT integration, producing AI-ready high-dimensional datasets. It is sold as annual enterprise subscriptions to pharmaceutical, biotech, diagnostics, and academic customers, supplemented by specialist training and on-site implementation support.

Is Synthace a public or private company?

Synthace is a private company. It is classified as venture growth investor backed and is currently operating.

When was Synthace founded?

Synthace was founded in 2011. It employs 11 to 50 people.

Where is Synthace based?

Synthace is headquartered in London, United Kingdom, in the Europe region.

How does Synthace make money?

Three revenue lines are on record. Software Platform Subscription is the primary driver. The others are protocols and Trusted Protocols and training and On-Site Support.

Who are Synthace's main competitors?

Direct peers on record are Benchling, Dotmatics, LabVantage, LabWare, TetraScience and Genedata. Emerging players are IDBS, Scitara and LabArchives. Insitro is listed as an others.

Does Synthace have an API?

No public API is recorded for Synthace.

What industry is Synthace in?

Synthace's product category is Life Sciences R&D Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nirdoshjagota7 Best Biofoundry Automation Software ToolsSeven biofoundry automation software tools are ranked, including Cellario, Green Button Go, TeselaGen, Synthace, Hamilton Venus, Biomek Software, and Opentrons. The guide categorizes them by orchestration, execution, and workflow management, advising selection based on lab bottlenecks, team capability, and scale path.Drug Discovery World (DDW)SLAS2026: AI, automation and high-throughput systems dominateMultiple life sciences companies made product launches and announcements at SLAS2026, with a strong focus on AI-powered tools, automation systems, and high-throughput screening platforms for drug discovery. Notable launches included Carterra's 48-channel SPR instrument, Cenevo's AI agents for lab operations, and Revvity's new discovery platforms, while several collaborations such as Charles River's partnership with Synthace were also announced. The event highlights a broader industry trend toward miniaturization, automation, and AI integration in laboratory workflows to accelerate drug discovery processes.RdworldonlineSLAS 2026 show floor roundup: Partnerships, kits and new categoriesSLAS 2026 in Boston featured multiple partnerships, kit launches, and new technology categories addressing bottlenecks in drug discovery and lab operations. SPT Labtech and BellBrook Labs unveiled a miniaturized cancer screening platform targeting VPS4B ATPase with high hit rates, while Synthace partnered with Charles River Laboratories to integrate DoE software into assay development services. Additional announcements included Omega Bio-tek's automation-ready purification kits, Openshelf's lab inventory automation robot, and Tangible Scientific's compound management platform, along with surveys showing 65% of scientists have repeated experiments due to hard-to-find prior results.PR NewswireSynthace Announces Appointment of Willem Baralt as New ChairmanSynthace appointed Willem Baralt as Chairman of the Board, joining in February 2024. He previously led Quanta Dialysis Technologies, securing $245M Series D. The appointment aims to integrate AI capabilities into its digital experimentation platform.Business Wire BlogSynthace, a Digital Experiment Platform for Life Science R&D, Records Strongest Year YetSynthace reported its strongest year on record, with 94% annual recurring revenue growth and 166% total contract value growth. The company also saw 170% net revenue retention and double account growth, with deployments in 10 of the top 20 pharma companies.PR NewswireThe Worldwide Laboratory Informatics Industry is Anticipated to Reach $12.6 Billion by 2032: Reduced Human Error and Increased Efficiency is Driving GrowthResearch and Markets published a report estimating the global laboratory informatics market will grow from $4,341.2 million in 2021 to $12,677.0 million by 2032, representing a compound annual growth rate of 10.27%. The market growth is driven by increased laboratory efficiency, better data management, reduced human error, and time savings from adopting laboratory informatics systems. Key recent developments include Agilent Technologies' acquisition of AI technology from Virtual Control, Thermo Fisher Scientific's expanded multivendor control approach, PerkinElmer's launch of a cloud-based research suite, Abbott's STARLIMS platform upgrade, and a partnership between IDBS and Synthace for high-throughput process development.GlobeNewswireInsights on the Laboratory Informatics Global Market to 2032 - Players Include Merck, PerkinElmer, Thermo Fisher Scientific and WatersResearch and Markets published a market report on the global laboratory informatics market, valued at $4,341.2 million in 2021 and projected to reach $12,677.0 million by 2032, reflecting a CAGR of 10.27% during 2022-2032. The report highlights market growth drivers including reduced human error, time savings, and increasing adoption across industries, alongside challenges such as slow implementation speed and data migration complexities. Recent strategic developments include Agilent Technologies acquiring AI technology from Virtual Control, PerkinElmer launching a cloud-based research suite, Thermo Fisher expanding its software deployment on AWS, and partnerships such as IDBS (Danaher) collaborating with Synthace for bioprocess automation.PR NewswireIDBS and Synthace announce strategic partnership to streamline bioprocess data managementIDBS and Synthace have announced a strategic partnership to integrate Synthace's cloud-based automation platform with IDBS's Polar™ biopharma lifecycle management software, enabling high-throughput process development capabilities for biologics development teams. The combined solution automates the capture, structuring, and enrichment of experimental data across bioreactors and analytical instruments, allowing users to scale to hundreds of automated, parallelized experiments per month. The partnership aims to help biologics developers reduce time-to-IND while improving process robustness and product quality through better data management and decision-making.BusinessCloudSynthace raises £26m to automate drug developmentSynthace, a London-based life sciences software company, raised £26 million in Series C funding to automate drug development. The company plans to expand its US leadership team and deploy capital to transform scientific research. Seven of the top 10 global pharmaceutical companies have adopted its platform.Tech.euSynthace raises $35 million, helps scientists automate biology experimentation and insight sharingLondon-based life sciences company Synthace has raised $35 million in a Series C funding round led by Horizons Ventures and Sofinnova Partners. The capital will support commercial growth and hiring, aiming to expand adoption of its R&D cloud platform which automates biology experimentation for major pharmaceutical firms and agrichemical companies like Syngenta.